Joseph Quinn
Oregon Health & Science University, OR·Neuroscience
Alzheimer's disease and related dementias develop slowly, often for years before symptoms appear. Researchers need reliable biomarkers, measurable signs in blood, spinal fluid or DNA, to detect disease early and track how it changes.
- Fields
Neuroscience
Medicine & Clinical Research
- Topics
Alzheimer's disease
dementia
mild cognitive impairment
- Grants
- 1 known grant, through Mar 2030
What they work on
- Collect and provide DNA, plasma, peripheral blood mononuclear cells and cerebrospinal fluid from healthy controls, people with mild cognitive impairment and people with Alzheimer's disease and related dementias.
- Generate biomarker data, including ApoE genotype for all participants and plasma amyloid beta 40/42, p-tau-217, p-tau-181, total tau, neurofilament light and GFAP levels, measures of Alzheimer's-related protein buildup and brain injury.
- Measure newer markers tied to sleep and brain waste clearance, such as aquaporin-4 genetic variants, and levels of the antioxidant regulator NRF2 in blood cells, in selected participant groups.
- Support collaborative biomarker research on early dementia and disease progression, emphasizing the oldest old, Black and isolated older adults, and share samples and data with national dementia centers.
More about the research
Those samples are only useful if they are collected carefully, linked to good participant information and shared widely. This grant supports the Biomarker Core of the Oregon Alzheimer's Disease Research Center, which collects and supplies biomarker samples and data for dementia research.
Why it matters
Well-characterized samples and biomarker data could help researchers detect Alzheimer's disease and related dementias earlier, track meaningful change and test new treatments. Including under-represented groups such as the oldest old, Black older adults and rural or isolated people may make findings more applicable to the full range of patients affected by dementia.
Known grants
From NIH and NSF research grants. Labs often have other funding we can't see.
Closest labs
David Geldmacher
University of Alabama at Birmingham, AL·Neuroscience
Enroll and follow about 525 community volunteers each year, cognitively unimpaired, with mild cognitive impairment or with mild dementia, at least 40% Black or African American, using standard national tests plus social determinants of health, body composition and actigraphy measures.
Ling Wu
North Carolina Central University, NC·Neuroscience
Validate newly discovered phosphorylated tau (p-tau) markers for early Alzheimer's diagnosis, including distinguishing mild cognitive impairment from normal cognition, in patient plasma and cerebrospinal fluid.
Yunjie Tong
Purdue University, IN·Neuroscience
Measure how strongly changes in cerebral blood volume, the amount of blood in the brain, are coupled to cerebrospinal fluid (CSF) movement during both wake and sleep states.
The school
Oregon Health & Science University: 24 labs on PI Pages, $545M a year on research, 54 research doctorates a year.
Reach out
A start for your email. Fill in the brackets.